메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Samsung Biologics reports second quarter 2025 financial results

Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion Recorded Q2'25 consolidated operating profit of KRW 475.6 billion Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July 23, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025. "Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and Pr
- 김갑성 기자
- 2025-07-23 14:54
HIMSS APAC 2025: Malaysian Health Minister Visits GuidelineX Exhibition to Explore AI Clinical Decision Support System

KUALA LUMPUR, Malaysia, July 22, 2025 -- Dr. Dzulkefly Ahmad, Minister of Health of Malaysia, visited the GuidelineX exhibition at HIMSS APAC 2025, where he engaged in comprehensive discussions on AI-powered clinical decision support systems (CDSS). The minister examined the practical applications of GuidelineX's technology, which has supported 61 million inpatient visits and facilitated 1.4 billion outpatient visits annually across China, representing 25% and 33% of the national patient visits to hospitals, respectively. Dr. Ahmad noted Malaysia's ongoing efforts in digital health and
- 김갑성 기자
- 2025-07-22 22:20
BostonGene Receives Frost & Sullivan's 2025 North American Enabling Technology Leadership Award for Redefining Precision Oncology with AI and Multiomics Innovation

BostonGene's comprehensive AI-powered platform integrates multiomics data to accelerate discovery, reduce development risk and advance precision oncology across all stages the R&D continuum SAN ANTONIO, July 22, 2025 -- Frost & Sullivan has named BostonGene the recipient of the 2025 North American Enabling Technology Leadership Award in recognition of the company's pioneering role in advancing precision oncology. BostonGene's clinically validated, AI-powered platform uses a multimodal approach to decode disease and uncover predictive biological signatures. BostonGene c
- 김갑성 기자
- 2025-07-22 22:00
LG AI Research Showcases 'EXAONE Ecosystem' at LG AI Talk Concert 2025

[ 메디채널 김갑성 기자 ] Pioneering AI Transformation from Bio to Business Intelligence SEOUL, South Korea, July 22, 2025 -- LG AI Research hosted its "LG AI Talk Concert 2025" today at the LG Sciencepark Convergence Hall in Magok, Seoul, showcasing the evolution of its EXAONE ecosystem. The event highlighted the culmination of five years of AI development, featuring advanced AI models and services designed for real-world industrial applications. Woohyung Lim, Co-President of LG AI Research, outlined future plans, stating, "LG AI Research will secure global competitivene
- 김갑성 기자
- 2025-07-22 22:00
Kolmar Korea Launches Full Operation of 2nd US Factory, Establishing K-Beauty's 'Tariff Safe Zone' in America

New 17,805㎡ facility completed in Pennsylvania with an annual production capacity of 300 million units Full ODM production capabilities in the US — from color cosmetics to skincare and suncare — mitigating tariff and supply chain risks 'MADE BY KOLMAR' world-class manufacturing technology localized to the US market OLYPHANT, Pa. and SEOUL, South Korea, July 22, 2025 -- Kolmar Korea has officially completed construction and begun full-scale operations of its second manufacturing facility in the United States, the world's largest cosmetics market. Located in Scott Townsh
- 김갑성 기자
- 2025-07-22 20:30
A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US

All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months SYDNEY, July 22, 2025 -- Actinogen Medical Limited (ASX: ACW) is encouraging individuals and their loved ones affected by Alzheimer's disease to take part in a groundbreaking clinical trial that could transform the way we treat this devastating condition. The trial is enrolling people diagnosed with mild to moderate Alzheimer's disease, offering them a chance
- 김갑성 기자
- 2025-07-22 20:00
Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. Q2 2025 Highlights Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year. FY 2025 revenue guidance of $770 million to $800 million is reaffirmed. Gozellix® launched in the U.S. and commercial dose deliveries commenced. Gozel
- 김갑성 기자
- 2025-07-22 16:02
METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting

HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the rapid design of tissue-targeted lipid nanoparticles (LNPs), which exhibit high delivery efficiency, strong tissue specificity, and excellent translatability in non-human primates (NHPs). Founded in 1978, the Controlled Releas
- 김갑성 기자
- 2025-07-22 15:52
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

SHANGHAI, July 22, 2025 -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with an EGFR exon 19 deletion or L858R mutation with disease progression on or after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. &
- 김갑성 기자
- 2025-07-22 10:25
Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp of a Cure' White Paper examines Asia Pacific's readiness for the Precision Era – the current, transformative period where generically prescribed and regularly administered treatments are increasingly giving way to potentially curative therapies tailored to individuals and their disease. Treatments called pre
- 김갑성 기자
- 2025-07-22 10:07

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-09-01_MON

2025-08-31_SUN

2025-08-30_SAT

Global Trade Review Announces GTR Asia 2025 in Singapore - the premier platform for the trade community in the Asia Pacific region - hits over 1,500 registration for September 2-3 23:39

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 01일 09시 00분